Welcome to our dedicated page for Edwards Lifesciences news (Ticker: EW), a resource for investors and traders seeking the latest updates and insights on Edwards Lifesciences stock.
Edwards Lifesciences Corporation reports developments in structural heart medical technology, including surgical tissue valves, transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies. Company news commonly covers the SAPIEN TAVR platform, PASCAL transcatheter edge-to-edge repair technology, the EVOQUE transcatheter tricuspid valve replacement system, and RESILIA tissue used in surgical and transcatheter valve innovations.
Recurring updates include quarterly results, clinical-trial data presented at cardiovascular meetings, reimbursement and guideline developments affecting valve procedures, product pipeline commentary, healthcare conference appearances, access initiatives for structural heart treatment, and finance leadership or governance announcements.
Edwards Lifesciences (NYSE: EW) reported Q4 2025 sales of $1.57B (up 13.3%) and Q4 TAVR sales of $1.16B (up 12.0%). FY2025 sales rose 11.5% with full-year TAVR sales of $4.5B. Q4 adjusted EPS was $0.58. The company raised confidence in FY2026 guidance: constant-currency revenue +8–10% and adjusted EPS $2.90–3.05, with TMTT expected to grow 35–45% to $740–780M.
Cash was ~$3.0B and total debt ~$600M. Management cited trial data, guideline updates, new approvals, and product launches as catalysts for 2026 growth.
Edwards Lifesciences (NYSE: EW) will report operating results for the quarter ended December 31, 2025 after market close on Tuesday, February 10, 2026.
The company will host a live conference call at 5:00 p.m. ET the same day. Participants can dial (877) 704-2848 or (201) 389-0893, and a live/archived webcast will be available at ir.edwards.com. Media and investor contact emails are provided for follow-up.
Edwards Lifesciences (NYSE: EW) will present at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026. Scott Ullem, chief financial officer, is scheduled to present at 9:50 a.m. ET. A live webcast and same-day archived replay will be available on the company investor relations site.
Investors can access the webcast at http://ir.edwards.com/. Media and investor contact emails were provided for follow-up.
Edwards Lifesciences (NYSE: EW) said the U.S. District Court for the District of Columbia granted the U.S. Federal Trade Commission's motion for an injunction blocking Edwards' proposed acquisition of JenaValve Technology, and Edwards will not acquire JenaValve.
The company said it disagrees with the decision, reaffirmed its commitment to treating aortic regurgitation (AR), and will continue advancing the SOJOURN transcatheter AR valve and enrolling patients in the JOURNEY pivotal trial. Edwards revised full-year 2026 adjusted EPS guidance to $2.90–$3.05 from $2.80–$2.95 and will provide further updates at its Fourth Quarter earnings call in February.
Edwards Lifesciences (NYSE: EW) announced FDA approval of the SAPIEN M3 transcatheter mitral valve replacement system on December 23, 2025, the first U.S. transseptal transcatheter therapy for mitral regurgitation.
The device is indicated for symptomatic moderate-to-severe or severe mitral regurgitation in patients deemed unsuitable for surgery or TEER, and for mitral valve dysfunction associated with mitral annular calcification. One-year ENCIRCLE pivotal trial data (299 patients) showed 95.7% MR ≤0/1+ and that the trial met all primary and secondary endpoints; the system received CE Mark in April 2025.
Edwards Lifesciences (NYSE: EW) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026. Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT, and Scott Ullem, chief financial officer, will also participate.
A live webcast will be available on the company investor relations site at http://ir.edwards.com/, with an archived version posted later the same day. The announcement notes contact emails for media and investor inquiries.
Edwards Lifesciences (NYSE: EW) reaffirmed guidance and outlined strategy for sustainable growth at its annual investor conference on December 4, 2025. Management reiterated 2025 sales growth at the high end of 9%–10% and EPS of $2.56–$2.62. For 2026 the company guided $6.4–$6.8B sales (constant currency, 8%–10% growth) and adjusted EPS of $2.80–$2.95, including dilution from the planned JenaValve acquisition and ~100bps operating margin expansion at midpoint.
2026 segment targets include TAVR $4.6–$4.9B (6%–8% growth), TMTT $740–$780M (35%–45% growth), and Surgical $1.05–$1.13B. Management highlighted long-term targets: ~10% average annual sales growth and TMTT reaching $2B by 2030.
Edwards Lifesciences (NYSE: EW) announced a founding sponsorship of the American Heart Association’s Heart Valve Initiative on November 9, 2025 to improve care for the more than 28 million people with heart valve disease worldwide. The initiative aims to reduce U.S. deaths linked to valve disease (over 60,000 annually) by improving diagnosis, treatment access, clinician training, data collection, hospital certification, public reporting and patient education.
Planned actions span five years and build on the existing Target: Aortic Stenosis program to accelerate earlier recognition and faster treatment.
Edwards Lifesciences (NYSE: EW) announced that Chief Financial Officer Scott Ullem will transition from his CFO role by midyear 2026. The company is initiating a selection process to appoint a new CFO, and Ullem will remain in an advisory role after a successor is named. Management said the planned timing is intended to enable continuity and a smooth transfer of responsibilities during the transition.
Contact information for media and investors was provided. The release includes standard forward-looking statement disclosures and directs readers to the company website for filings and safety information.
Summary not available.